327 related articles for article (PubMed ID: 32542396)
1. Decoy ACE2-expressing extracellular vesicles that competitively bind SARS-CoV-2 as a possible COVID-19 therapy.
Inal JM
Clin Sci (Lond); 2020 Jun; 134(12):1301-1304. PubMed ID: 32542396
[TBL] [Abstract][Full Text] [Related]
2. Response by Gheblawi et al to Letter Regarding Article, "Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2".
Gheblawi M; Wang K; Viveiros A; Nguyen Q; Zhong JC; Turner AJ; Raizada MK; Grant MB; Oudit GY
Circ Res; 2020 Jul; 127(2):e46-e47. PubMed ID: 32614719
[No Abstract] [Full Text] [Related]
3. Letter by Weir Regarding Article, "Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2".
Weir RAP
Circ Res; 2020 Jul; 127(2):e44-e45. PubMed ID: 32614717
[No Abstract] [Full Text] [Related]
4. Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19).
Bourgonje AR; Abdulle AE; Timens W; Hillebrands JL; Navis GJ; Gordijn SJ; Bolling MC; Dijkstra G; Voors AA; Osterhaus AD; van der Voort PH; Mulder DJ; van Goor H
J Pathol; 2020 Jul; 251(3):228-248. PubMed ID: 32418199
[TBL] [Abstract][Full Text] [Related]
5. Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy?
Batlle D; Wysocki J; Satchell K
Clin Sci (Lond); 2020 Mar; 134(5):543-545. PubMed ID: 32167153
[TBL] [Abstract][Full Text] [Related]
6. Interaction of Human ACE2 to Membrane-Bound SARS-CoV-1 and SARS-CoV-2 S Glycoproteins.
Anand SP; Chen Y; Prévost J; Gasser R; Beaudoin-Bussières G; Abrams CF; Pazgier M; Finzi A
Viruses; 2020 Sep; 12(10):. PubMed ID: 33003587
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein Binding to ACE2 Receptors from Human, Pets, Farm Animals, and Putative Intermediate Hosts.
Zhai X; Sun J; Yan Z; Zhang J; Zhao J; Zhao Z; Gao Q; He WT; Veit M; Su S
J Virol; 2020 Jul; 94(15):. PubMed ID: 32404529
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin-converting enzyme 2: The old door for new severe acute respiratory syndrome coronavirus 2 infection.
Tan HW; Xu YM; Lau ATY
Rev Med Virol; 2020 Sep; 30(5):e2122. PubMed ID: 32602627
[TBL] [Abstract][Full Text] [Related]
9. Interaction of SARS-CoV-2 and Other Coronavirus With ACE (Angiotensin-Converting Enzyme)-2 as Their Main Receptor: Therapeutic Implications.
Davidson AM; Wysocki J; Batlle D
Hypertension; 2020 Nov; 76(5):1339-1349. PubMed ID: 32851855
[TBL] [Abstract][Full Text] [Related]
10. Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19.
Cheng H; Wang Y; Wang GQ
J Med Virol; 2020 Jul; 92(7):726-730. PubMed ID: 32221983
[TBL] [Abstract][Full Text] [Related]
11. Dynamics of the ACE2-SARS-CoV-2/SARS-CoV spike protein interface reveal unique mechanisms.
Ali A; Vijayan R
Sci Rep; 2020 Aug; 10(1):14214. PubMed ID: 32848162
[TBL] [Abstract][Full Text] [Related]
12. Searching therapeutic strategy of new coronavirus pneumonia from angiotensin-converting enzyme 2: the target of COVID-19 and SARS-CoV.
Li SR; Tang ZJ; Li ZH; Liu X
Eur J Clin Microbiol Infect Dis; 2020 Jun; 39(6):1021-1026. PubMed ID: 32285293
[TBL] [Abstract][Full Text] [Related]
13. Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus.
Wan Y; Shang J; Graham R; Baric RS; Li F
J Virol; 2020 Mar; 94(7):. PubMed ID: 31996437
[TBL] [Abstract][Full Text] [Related]
14. SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy.
Datta PK; Liu F; Fischer T; Rappaport J; Qin X
Theranostics; 2020; 10(16):7448-7464. PubMed ID: 32642005
[TBL] [Abstract][Full Text] [Related]
15. A brief review of interplay between vitamin D and angiotensin-converting enzyme 2: Implications for a potential treatment for COVID-19.
Malek Mahdavi A
Rev Med Virol; 2020 Sep; 30(5):e2119. PubMed ID: 32584474
[TBL] [Abstract][Full Text] [Related]
16. Physiological and pathological regulation of ACE2, the SARS-CoV-2 receptor.
Li Y; Zhou W; Yang L; You R
Pharmacol Res; 2020 Jul; 157():104833. PubMed ID: 32302706
[TBL] [Abstract][Full Text] [Related]
17. Angiotensin-converting enzyme 2 in severe acute respiratory syndrome coronavirus and SARS-CoV-2: A double-edged sword?
Yan T; Xiao R; Lin G
FASEB J; 2020 May; 34(5):6017-6026. PubMed ID: 32306452
[TBL] [Abstract][Full Text] [Related]
18. Outsmarting SARS-CoV-2 by empowering a decoy ACE2.
Sokolowska M
Signal Transduct Target Ther; 2020 Nov; 5(1):260. PubMed ID: 33144557
[No Abstract] [Full Text] [Related]
19. Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding.
Byrnes JR; Zhou XX; Lui I; Elledge SK; Glasgow JE; Lim SA; Loudermilk RP; Chiu CY; Wang TT; Wilson MR; Leung KK; Wells JA
mSphere; 2020 Sep; 5(5):. PubMed ID: 32938700
[TBL] [Abstract][Full Text] [Related]
20. Monoclonal antibodies for the S2 subunit of spike of SARS-CoV-1 cross-react with the newly-emerged SARS-CoV-2.
Zheng Z; Monteil VM; Maurer-Stroh S; Yew CW; Leong C; Mohd-Ismail NK; Cheyyatraivendran Arularasu S; Chow VTK; Lin RTP; Mirazimi A; Hong W; Tan YJ
Euro Surveill; 2020 Jul; 25(28):. PubMed ID: 32700671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
